A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults - Orito, Yuji; Otani, Naoyuki; Matsumoto, Yuki; Fujimoto, Katsukuni; Oshima, Nobuyuki; Maas, Brian M.; Caro, Luzelena; Aliprantis, Antonios O.; Cox, Kara S.; Tokumaru, Osamu; Kodama, Masaaki; Kudo, Hideo; et al. (Clinical and Translational Science, 2022)
Keywords: Adult; Age; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Babies; Bioavailability; Disease; Diseases; Dosage; Drug dosages; Drug therapy; Hospital costs; Hospitalization; Humans; Infant; Infants; Infections; Intravenous administration; Japan; Laboratories; Monoclonal antibodies; Morbidity; Mortality; Palivizumab; Pharmacodynamics; Pharmacokinetics; Placebos; Population; Proteins; Public aspects of medicine; RA1-1270; Respiratory syncytial virus; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Respiratory tract diseases; RM1-950; Seasons; Surveillance; Therapeutics. Pharmacology; Vaccines; Viral infections; Vital signs; Japan